Is This a 737 Max Moment for Brolucizumab?

Journal article

Open access

Peer reviewed

Philip J Rosenfeld and David J Browning

American journal of ophthalmology, Vol.216, pp.A7-A8

2020-08

PMID: 32505363

Abstract

Angiogenesis Inhibitors - adverse effects

Antibodies, Monoclonal, Humanized - adverse effects

Drug-Related Side Effects and Adverse Reactions - etiology

Humans

Intravitreal Injections

Retinal Vasculitis - chemically induced

Uveitis - chemically induced

Vascular Endothelial Growth Factor A - antagonists & inhibitors

Wet Macular Degeneration - drug therapy

url

https://doi.org/10.1016/j.ajo.2020.05.012View

Published (Version of record) Open

14 Record Views

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.36 Ophthalmology; 1.36.383 Diabetic Retinopathy
Web Of Science research areas: Ophthalmology
ESI research areas: Clinical Medicine

This output has contributed to the advancement of the following goals:

Source: InCites

Title: Is This a 737 Max Moment for Brolucizumab?
Creators: Philip J Rosenfeld - Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: prosenfeld@miami.edu
David J Browning - Charlotte Eye, Ear, Nose, and Throat Associates, Charlotte, North Carolina, USA
Publication Details: American journal of ophthalmology, Vol.216, pp.A7-A8
Academic Unit: Miller School of Medicine; UMMG Department of Ophthalmology
Language: English
Resource Type: Journal article
PMID: 32505363
Record Identifier: 991031614848002976